[go: up one dir, main page]

NZ761076B2 - Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases - Google Patents

Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases

Info

Publication number
NZ761076B2
NZ761076B2 NZ761076A NZ76107618A NZ761076B2 NZ 761076 B2 NZ761076 B2 NZ 761076B2 NZ 761076 A NZ761076 A NZ 761076A NZ 76107618 A NZ76107618 A NZ 76107618A NZ 761076 B2 NZ761076 B2 NZ 761076B2
Authority
NZ
New Zealand
Prior art keywords
acid
use according
composition
comprised
citric acid
Prior art date
Application number
NZ761076A
Other versions
NZ761076A (en
Inventor
Paolo Luca Maria Giorgetti
Original Assignee
Professional Dietetics Spa
Filing date
Publication date
Priority claimed from IT102017000087376A external-priority patent/IT201700087376A1/en
Application filed by Professional Dietetics Spa filed Critical Professional Dietetics Spa
Publication of NZ761076A publication Critical patent/NZ761076A/en
Publication of NZ761076B2 publication Critical patent/NZ761076B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Abstract

Composition for promoting mitochondrial biogenesis and improving mitochondrial function in a subject, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid. In particular, the present invention relates to the use of a composition in the manufacture of a medicament for treatment and/or prevention of a mitochondrial dysfunction related disease that is obesity in a subject, wherein the composition comprises an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid.

Claims (22)

1. Use of a composition in the manufacture of a medicament for treatment and/or prevention of a 5 mitochondrial dysfunction related disease that is obesity in a subject, wherein the composition comprises an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid.
2. Use according to claim 1, wherein the weight ratio between the sum of citric acid, malic acid, succinic acid and the sum of the branched chain amino acids leucine, isoleucine, valine plus lysine and threonine 15 in the composition is comprised between 0.05 and 0.3.
3. Use according to claim 1, wherein the weight ratio between the sum of citric acid, malic acid, succinic acid and the sum of the branched chain amino acids 20 leucine, isoleucine, valine plus lysine and threonine in the composition is comprised between 0.1 and 0.25.
4. Use according to any one of the preceding claims, wherein the weight ratio between the overall amount of 25 citric acid, malic acid, succinic acid and the overall amount of the branched chain amino acids leucine, isoleucine, valine in the composition is comprised between 0.1 and 0.4. 30
5. Use according to any one of claims 1 to 3, wherein the weight ratio between the overall amount of citric acid, malic acid, succinic acid and the overall amount of the branched chain amino acids leucine, isoleucine, valine in the composition is comprised between 0.15 and 35 0.35.
6. Use according to any one of the preceding claims, wherein the weight ratio between citric acid and the sum of malic acid and succinic acid in the 5 composition is comprised between 1.0 and 4.0.
7. Use according to any one of claims 1 to 5, wherein the weight ratio between citric acid and the sum of malic acid and succinic acid in the composition 10 is comprised between 1.5 and 2.5.
8. Use according to any one of the preceding claims, wherein the citric acid:malic acid:succinic acid weight ratio in the composition is comprised 15 between 10:1:1 and 2:1.5:1.5.
9. Use according to any one of claims 1 to 8, wherein the citric acid:malic acid:succinic acid weight ratio in the composition is comprised between 7:1:1 and 20 1.5:1:1.
10. Use according to any one of claims 1 to 8, wherein the citric acid:malic acid:succinic acid weight ratio in the composition is comprised between 5:1:1 and 25 3:1:1.
11. Use according to any one of the preceding claims, wherein said active agent further comprises at least one amino acid selected in the group consisting of 30 histidine, phenylalanine, methionine, tryptophan, tyrosine, cysteine.
12. Use according to any one of the preceding claims, wherein said active agent further comprises histidine, 35 phenylalanine, methionine, tryptophan, cysteine and optionally tyrosine.
13. Use according to any one of the preceding claims, wherein the ratio between the overall molar amount of citric acid, malic acid, succinic acid and the overall 5 molar amount of methionine, phenylalanine, histidine and tryptophan in the composition is higher than 1.35.
14. Use according to any one of the preceding claims, wherein the ratio between the overall molar amount of 10 the three acids citric acid, succinic acid, malic acid and the overall molar amount of lysine and threonine in the composition is comprised between 0.1 and 0.7.
15. Use according to any one of claims 1 to 13, wherein 15 the ratio between the overall molar amount of the three acids citric acid, succinic acid, malic acid and the overall molar amount of lysine and threonine in the composition is comprised preferably between 0.15 and 0.55.
16. Use according to any one of the preceding claims, wherein the weight or molar amount of citric acid in the composition is higher than the overall weight or molar amount of malic acid and succinic acid.
17. Use according to any one of the preceding claims, wherein the weight ratio between leucine and citric acid in the composition is comprised between 5 and 1. 30 18. Use according to any one of claims 1 to 16, wherein the weight ratio between leucine and citric acid in the composition is comprised between 2.50 and
18. 50. 35
19. Use according to any one of the preceding claims, wherein said active agent is free of arginine.
20. Use according to any one of the preceding claims, wherein the composition further comprises one or more 5 vitamins.
21. Use according to claim 20, wherein the one or more vitamins is selected from the group of vitamin B. 10
22. Use according to claim 21, where the vitamins are vitamin B1 and/or vitamin B6.
NZ761076A 2018-07-20 Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases NZ761076B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102017000087376A IT201700087376A1 (en) 2017-07-28 2017-07-28 COMPOSITIONS INCLUDING AMINO ACIDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION
PCT/IB2018/055428 WO2019021137A1 (en) 2017-07-28 2018-07-20 Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases

Publications (2)

Publication Number Publication Date
NZ761076A NZ761076A (en) 2025-02-28
NZ761076B2 true NZ761076B2 (en) 2025-06-04

Family

ID=

Similar Documents

Publication Publication Date Title
MY200975A (en) "Compositions Comprising Amino acids for use in the Treatment of Mitochondrial Dysfunction-Related Diseases"
JP2018012722A5 (en)
WO2015120110A3 (en) Novel pharmaceutical formulations
PH12020552254A1 (en) Compositions comprising amino acids for use in the prevention and treatment of liver diseases
WO2011107653A8 (en) Use of levodopa, carbidopa and entacapone for treating parkinson's disease
EP4349359A3 (en) Peptide exhibiting wrinkle-improving activity and uses thereof
WO2017022962A8 (en) Composition for preventing or treating immune disease, comprising ripk inhibitor as active ingredient
EA202090276A1 (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ANEMIA
PH12020500189A1 (en) Compositions comprising amino acids for use in the treatment of mitochondrial dysfuntion-related diseases
EP4400098A3 (en) Co-amorphous forms of beta-lactoglobulin and a drug substance
EA202191880A1 (en) COMPOSITIONS CONTAINING AMINO ACIDS FOR APPLICATION AND TREATMENT OF INJURIES OF THE CENTRAL NERVOUS SYSTEM
HRP20210010T1 (en) Injectable pharmaceutical formulations of lefamulin
WO2021044231A3 (en) Compounds comprising curcumin and basic amino acids
NZ761076B2 (en) Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases
NZ761073B2 (en) Compositions comprising amino acids for use in the treatment of mitochondrial dysfunction-related diseases
MX2023001572A (en) Solid dosage forms of palbociclib.
MX2022012693A (en) Composition comprising methylfolate.
RU2010130889A (en) COMPOSITION FOR THE TREATMENT OF NON-INFECTIOUS INFLAMMATION
RU2022106848A (en) COMPOSITIONS CONTAINING AMINO ACIDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTIONS
NZ598673A (en) Fat accumulation suppressor
WO2022200553A3 (en) Immune stimulating nanoparticle composition
PH12020500001A1 (en) Non-pulsatile prolonged-release betahistine oral solid compositions
TH2001000484A (en) An amino acid-containing constituent for the treatment of diseases associated with dysfunction of microtons.
MX2021013489A (en) Pharmaceutical combination comprising trazodone for the treatment of neuropathic pain.
MX2021007992A (en) Nail compositions having antifungal properties.